392 related articles for article (PubMed ID: 23473032)
1. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation.
Gameiro PA; Yang J; Metelo AM; Pérez-Carro R; Baker R; Wang Z; Arreola A; Rathmell WK; Olumi A; López-Larrubia P; Stephanopoulos G; Iliopoulos O
Cell Metab; 2013 Mar; 17(3):372-85. PubMed ID: 23473032
[TBL] [Abstract][Full Text] [Related]
2. Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.
Okazaki A; Gameiro PA; Christodoulou D; Laviollette L; Schneider M; Chaves F; Stemmer-Rachamimov A; Yazinski SA; Lee R; Stephanopoulos G; Zou L; Iliopoulos O
J Clin Invest; 2017 May; 127(5):1631-1645. PubMed ID: 28346230
[TBL] [Abstract][Full Text] [Related]
3. Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia.
Metallo CM; Gameiro PA; Bell EL; Mattaini KR; Yang J; Hiller K; Jewell CM; Johnson ZR; Irvine DJ; Guarente L; Kelleher JK; Vander Heiden MG; Iliopoulos O; Stephanopoulos G
Nature; 2011 Nov; 481(7381):380-4. PubMed ID: 22101433
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
5. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
Niu X; Zhang T; Liao L; Zhou L; Lindner DJ; Zhou M; Rini B; Yan Q; Yang H
Oncogene; 2012 Feb; 31(6):776-86. PubMed ID: 21725364
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability.
Wise DR; Ward PS; Shay JE; Cross JR; Gruber JJ; Sachdeva UM; Platt JM; DeMatteo RG; Simon MC; Thompson CB
Proc Natl Acad Sci U S A; 2011 Dec; 108(49):19611-6. PubMed ID: 22106302
[TBL] [Abstract][Full Text] [Related]
7. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.
Petrella BL; Brinckerhoff CE
Cancer Biol Ther; 2009 Jul; 8(14):1389-401. PubMed ID: 19483472
[TBL] [Abstract][Full Text] [Related]
8. ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma.
Carew JS; Esquivel JA; Espitia CM; Schultes CM; Mülbaier M; Lewis JD; Janssen B; Giles FJ; Nawrocki ST
PLoS One; 2012; 7(1):e31120. PubMed ID: 22295124
[TBL] [Abstract][Full Text] [Related]
9. (1)H NMR metabolomics analysis of renal cell carcinoma cells: Effect of VHL inactivation on metabolism.
Cuperlovic-Culf M; Cormier K; Touaibia M; Reyjal J; Robichaud S; Belbraouet M; Turcotte S
Int J Cancer; 2016 May; 138(10):2439-49. PubMed ID: 26620126
[TBL] [Abstract][Full Text] [Related]
10. Emetine promotes von Hippel-Lindau-independent degradation of hypoxia-inducible factor-2α in clear cell renal carcinoma.
Kong HS; Lee S; Beebe K; Scroggins B; Gupta G; Lee MJ; Jung YJ; Trepel J; Neckers L
Mol Pharmacol; 2010 Dec; 78(6):1072-8. PubMed ID: 20813864
[TBL] [Abstract][Full Text] [Related]
11. Vhl deletion in renal epithelia causes HIF-1α-dependent, HIF-2α-independent angiogenesis and constitutive diuresis.
Schönenberger D; Rajski M; Harlander S; Frew IJ
Oncotarget; 2016 Sep; 7(38):60971-60985. PubMed ID: 27528422
[TBL] [Abstract][Full Text] [Related]
12. VHL-HIF-2α axis-induced SMYD3 upregulation drives renal cell carcinoma progression via direct trans-activation of EGFR.
Liu C; Liu L; Wang K; Li XF; Ge LY; Ma RZ; Fan YD; Li LC; Liu ZF; Qiu M; Hao YC; Shi ZF; Xia CY; Strååt K; Huang Y; Ma LL; Xu D
Oncogene; 2020 May; 39(21):4286-4298. PubMed ID: 32291411
[TBL] [Abstract][Full Text] [Related]
13. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
[TBL] [Abstract][Full Text] [Related]
14. Formation of Renal Cysts and Tumors in Vhl/Trp53-Deficient Mice Requires HIF1α and HIF2α.
Schönenberger D; Harlander S; Rajski M; Jacobs RA; Lundby AK; Adlesic M; Hejhal T; Wild PJ; Lundby C; Frew IJ
Cancer Res; 2016 Apr; 76(7):2025-36. PubMed ID: 26759234
[TBL] [Abstract][Full Text] [Related]
15. VHL-deficiency leads to reductive stress in renal cells.
Vellama H; Eskla KL; Eichelmann H; Hüva A; Tennant DA; Thakker A; Roberts J; Jagomäe T; Porosk R; Laisk A; Oja V; Rämma H; Volke V; Vasar E; Luuk H
Free Radic Biol Med; 2023 Nov; 208():1-12. PubMed ID: 37506952
[TBL] [Abstract][Full Text] [Related]
16. von Hippel-Lindau mutants in renal cell carcinoma are regulated by increased expression of RSUME.
Tedesco L; Elguero B; Pacin DG; Senin S; Pollak C; Garcia Marchiñena PA; Jurado AM; Isola M; Labanca MJ; Palazzo M; Yankilevich P; Fuertes M; Arzt E
Cell Death Dis; 2019 Mar; 10(4):266. PubMed ID: 30890701
[TBL] [Abstract][Full Text] [Related]
17. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.
Choueiri TK; Fay AP; Gagnon R; Lin Y; Bahamon B; Brown V; Rosenberg JE; Hutson TE; Baker-Neblett KL; Carpenter C; Liu Y; Pandite L; Signoretti S
Clin Cancer Res; 2013 Sep; 19(18):5218-26. PubMed ID: 23881929
[TBL] [Abstract][Full Text] [Related]
18. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy.
Turcotte S; Chan DA; Sutphin PD; Hay MP; Denny WA; Giaccia AJ
Cancer Cell; 2008 Jul; 14(1):90-102. PubMed ID: 18598947
[TBL] [Abstract][Full Text] [Related]
19. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.
Smith K; Gunaratnam L; Morley M; Franovic A; Mekhail K; Lee S
Cancer Res; 2005 Jun; 65(12):5221-30. PubMed ID: 15958567
[TBL] [Abstract][Full Text] [Related]
20. Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism.
Leisz S; Schulz K; Erb S; Oefner P; Dettmer K; Mougiakakos D; Wang E; Marincola FM; Stehle F; Seliger B
Oncotarget; 2015 May; 6(13):11395-406. PubMed ID: 25890500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]